Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 04, 2025 07:00 ET | Source: GT Biopharma, Inc.

GT Biopharma to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

The Company is available for one-on-one meetings at the H.C. Wainwright Conference September 8-10, 2025 in New York City Phase 1 trial evaluating GTBP-3650 for the treatment of relapsed or refractory...
August 14, 2025 16:05 ET | Source: GT Biopharma, Inc.

GT Biopharma Reports Second Quarter 2025 Financial Results

GTB-3650 TriKE® Phase 1 trial has successfully completed Cohort 1 and Cohort 2 dosing, treating a total of four patients; following Cohort 2’s formal safety review, it has advanced into Cohort 3 and...
June 13, 2025 09:00 ET | Source: GT Biopharma, Inc.

GT Biopharma Appoints New Member to its Board of Directors

SAN FRANCISCO, CALIFORNIA, June 13, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics...
May 14, 2025 07:00 ET | Source: GT Biopharma, Inc.

GT Biopharma Appoints New Member to its Board of Directors

SAN FRANCISCO, CALIFORNIA, May 14, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics...
February 25, 2025 07:00 ET | Source: GT Biopharma, Inc.

GT Biopharma Announces Request for Withdrawal of Form S-1 Registration Statement

SAN FRANCISCO, CALIFORNIA, Feb. 25, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics...
November 14, 2024 16:00 ET | Source: GT Biopharma, Inc.

GT Biopharma Reports Third Quarter 2024 Financial Results

GTB-3650 TriKE® Phase 1 trial first patient dosed expected in Q4 2024; initial clinical data expected in Q2 2025GTB-5550 TriKE® IND submission for treatment of B7H3 positive solid tumors expected in...
September 24, 2024 09:15 ET | Source: GT Biopharma, Inc.

GT Biopharma to Host Virtual KOL Event Showcasing its NK Cell Engager Pipeline and Broad Indication Potential on October 10, 2024

SAN FRANCISCO, CALIFORNIA, Sept. 24, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative...
May 15, 2024 17:00 ET | Source: GT Biopharma, Inc.

GT Biopharma Reports First Quarter 2024 Financial Results and Provides Corporate Update

IND clearance for GTB-3650, a 2nd generation nanobody TriKE® for treatment of CD33+ leukemia expected in Q2 2024Phase 1 trial initiation with GTB-3650 expected in 2H 2024Anticipate IND submission for...
February 22, 2024 10:30 ET | Source: MAIA Biotechnology, Inc.

MAIA Biotechnology Completes Enrollment in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer

Topline data expected in second half of 2024THIO-101 will be the first completed clinical study of a telomere targeting agent in the field of cancer drug discovery and treatment CHICAGO, IL, Feb. ...
July 13, 2023 09:08 ET | Source: Invectys, Inc.

Invectys Announces Initiation of Phase 1/2a Clinical Trial in Solid Tumors and Change in Leadership

Houston, TX, USA, July 13, 2023 (GLOBE NEWSWIRE) -- Invectys, Inc., a clinical-stage immuno-oncology company developing novel therapies for the treatment of advanced cancers, today announces it has...